Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA

Signalling pathways of the TNF superfamily: a double-edged sword

Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793 · see citing works

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · see citing works

Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA

Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662 · see citing works

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G. X., Borkowsky, W., Farthing, C., & Ho, D. D. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4650-4655.1994 · Cited by 2,494 · see citing works

mRNA-based therapeutics--developing a new class of drugs

Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · see citing works

Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes

Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Rácz, P., Tenner‐Racz, K., Dalesandro, M. R., Scallon, B. J., et al. (1999) · Science · doi:10.1126/science.283.5403.857 · Cited by 2,167 · see citing works

Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412

Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · see citing works

Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · see citing works

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

Borrow, P., Lewicki, H. A., Hahn, B. H., Shaw, G. M., & Oldstone, M. B. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.6103-6110.1994 · Cited by 1,880 · see citing works

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

Betts, M. R. (2006) · Blood · doi:10.1182/blood-2005-12-4818 · Cited by 1,812 · see citing works

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,771 · see citing works

Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation

Betts, M. R., Brenchley, J. M., Price, D. A., Rosa, S. C. D., Douek, D. C., Roederer, M., & Koup, R. A. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00265-5 · Cited by 1,587 · see citing works

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M. A., Monard, S. P., Segal, J. P., Cao, Y., Rowland‐Jones, S., Cerundolo, V., et al. (1998) · Science · doi:10.1126/science.279.5359.2103 · Cited by 1,381 · see citing works

A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1

Fellay, J., Shianna, K. V., Ge, D., Colombo, S. F., Ledergerber, B., Weale, M., Zhang, K., Gumbs, C. E., Castagna, A., Cossarizza, A., et al. (2007) · Science · doi:10.1126/science.1143767 · Cited by 1,231 · see citing works

HLAand HIV-1: Heterozygote Advantage andB*35-Cw*04Disadvantage

Carrington, M. N., Nelson, G. W., Martin, M. P., Kissner, T. L., Vlahov, D., Goedert, J. J., Kaslow, R. A., Buchbinder, S., Hoots, K. W., & O’Brien, S. J. (1999) · Science · doi:10.1126/science.283.5408.1748 · Cited by 1,220 · see citing works

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

Goulder, P., Phillips, R. E., Colbert, R. A., McAdam, S. N., Ogg, G. S., Nowak, M. A., Giangrande, P. L. F., Luzzi, G. A., Morgana, B., Edwards, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-212 · Cited by 1,115 · see citing works

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

Kiepiela, P., Ngumbela, K. C., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E. S., Reddy, S., de Pierres, C., Mncube, Z., Mkhwanazi, N. P., et al. (2006) · Nature Medicine · doi:10.1038/nm1520 · Cited by 1,033 · see citing works

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

Migueles, S. A., Laborico, A. C., Shupert, W. L., Sabbaghian, M. S., Rabin, R. L., Hallahan, C. W., van Baarle, D., Kostense, S., Miedema, F. F., McLaughlin, M. E., et al. (2002) · Nature Immunology · doi:10.1038/ni845 · Cited by 1,004 · see citing works

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

Hansen, S. G., Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-Johnson, L., Whizin, N., Oswald, K. A., Shoemaker, R. S., Swanson, T., et al. (2011) · Nature · doi:10.1038/nature10003 · Cited by 989 · see citing works

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884 · see citing works

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection

Salazar-Gonzalez, J. F., Salazar, M. G., Keele, B. F., Learn, G. H., Giorgi, E. E., Li, H., Decker, J. M., Wang, S., Baalwa, J., Kraus, M. H., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090378 · Cited by 763 · see citing works

The Influence ofHLAGenotype on AIDS

Carrington, M. N., & O’Brien, S. J. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152346 · Cited by 725 · see citing works

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

Almeida, J. R., Price, D. A., Papagno, L., Arkoub, Z. A., Sauce, D., Bornstein, E. R., Asher, T. E., Samri, A., Schnuriger, A., Theodorou, I. D., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070784 · Cited by 708 · see citing works

Innate Recognition of Viruses

Pichlmair, A., & Sousa, C. R. E. (2007) · Immunity · doi:10.1016/j.immuni.2007.08.012 · Cited by 690 · see citing works

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

Hansen, S. G., Vieville, C., Whizin, N., Coyne-Johnson, L., Siess, D. C., Drummond, D. D., Legasse, A. W., Jarvis, M. A., Oswald, K. A., Trubey, C. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1935 · Cited by 674 · see citing works

Advances in the delivery of RNA therapeutics: from concept to clinical reality

Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656 · see citing works

Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

Worm, S. W., Sabin, C. A., Weber, R. K., Reiss, P., El-Sadr, W. M., Dabis, F., Wit, S. D., Law, M. G., Monforte, A. D., Friis‐Møller, N., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/649897 · Cited by 644 · see citing works

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

Goonetilleke, N. P., Liu, M. K. P., Salazar-Gonzalez, J. F., Ferrari, G., Giorgi, E. E., Ganusov, V. V., Keele, B. F., Learn, G. H., Turnbull, E. L., Salazar, M. G., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090365 · Cited by 641 · see citing works

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells

Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625 · see citing works

Immune clearance of highly pathogenic SIV infection

Hansen, S. G., Piatak, M., Ventura, A. B., Hughes, C. M., Gilbride, R. M., Ford, J. C., Oswald, K. A., Shoemaker, R. S., Li, Y., Lewis, M. S., et al. (2013) · Nature · doi:10.1038/nature12519 · Cited by 598 · see citing works

Evolution and transmission of stable CTL escape mutations in HIV infection

Goulder, P., Brander, C., Tang, Y., Tremblay, C. L., Colbert, R. A., Addo, M. M., Rosenberg, E. S., Nguyen, T. H. O., Allen, R. L., Piechocka‐Trocha, A., et al. (2001) · Nature · doi:10.1038/35085576 · Cited by 542 · see citing works

Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses

Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501 · see citing works

Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques

Matano, T., Shibata, R., Siemon, C., Connors, M., Lane, H. C., & Martin, M. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.164-169.1998 · Cited by 487 · see citing works

Cytomegalovirus Vectors Violate CD8 + T Cell Epitope Recognition Paradigms

Hansen, S. G., Sacha, J. B., Hughes, C. M., Ford, J. C., Burwitz, B. J., Scholz, I., Gilbride, R. M., Lewis, M. S., Gilliam, A. N., Ventura, A. B., et al. (2013) · Science · doi:10.1126/science.1237874 · Cited by 433 · see citing works

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and <i>Toxoplasma gondii</i> challenges with a single dose

Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414 · see citing works

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells

Rubio, V., Stuge, T. B., Singh, N. S., Betts, M. R., Weber, J. S., Roederer, M., & Lee, P. P. (2003) · Nature Medicine · doi:10.1038/nm942 · Cited by 400 · see citing works

Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Pawelec, G., Hoerr, I., Rammensee, H.-G., & Garbe, C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a00068 · Cited by 378 · cited 1× · see citing works

A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines

Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338 · see citing works

HIV and HLA Class I: An Evolving Relationship

Goulder, P., & Walker, B. D. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.005 · Cited by 325 · see citing works

Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions

Zimmermann, A. E., Pizzoferrato, T., Bedford, J., Morris, A., Hoffman, R., & Braden, G. L. (2005) · Clinical Infectious Diseases · doi:10.1086/499048 · Cited by 314 · see citing works

Broadly targeted CD8 + T cell responses restricted by major histocompatibility complex E

Hansen, S. G., Wu, H. L., Burwitz, B. J., Hughes, C. M., Hammond, K. B., Ventura, A. B., Reed, J. S., Gilbride, R. M., Ainslie, E., Morrow, D. W., et al. (2016) · Science · doi:10.1126/science.aac9475 · Cited by 290 · see citing works

Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine

Létourneau, S., Im, E., Mashishi, T., Brereton, C., Bridgeman, A., Yang, H., Dorrell, L., Dong, T., Korber, B., McMichael, A. J., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000984 · Cited by 280 · see citing works

High Acceptability of HIV Pre-exposure Prophylaxis but Challenges in Adherence and Use: Qualitative Insights from a Phase I Trial of Intermittent and Daily PrEP in At-Risk Populations in Kenya

van der Elst, E. M., Mbogua, J., Operario, D., Mutua, G. N., Kuo, C., Mugo, P. M., Kanungi, J., Singh, S., Haberer, J. E., Priddy, F. H., et al. (2012) · AIDS and Behavior · doi:10.1007/s10461-012-0317-8 · Cited by 271 · see citing works

Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines

Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.202 · Cited by 248 · see citing works

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

Kuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Gene Therapy · doi:10.1038/gt.2010.52 · Cited by 226 · see citing works

Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals

Kreiter, S., Selmi, A., Diken, M., Sebastian, M., Osterloh, P., Schild, H., Huber, C., Türeci, Ö., & Şahin, U. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.309 · Cited by 221 · see citing works

Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study

Dalmasso, C., Carpentier, W., Meyer, L., Rouzioux, C., Goujard, C., Chaix, M., Lambotte, O., Avettand-Fenoel, V., Clerc, S. L., de Senneville, L. D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003907 · Cited by 213 · see citing works

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs

Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 212 · see citing works

Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design

Pepini, T., Pulichino, A.-M., Carsillo, T., Carlson, A. L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J. C., Maruggi, G., Otten, G. R., Geall, A. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601877 · Cited by 208 · see citing works

Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1

Borthwick, N., Ahmed, T., Ondondo, B., Hayes, P., Rose, A., Ebrahimsa, U., Hayton, E., Black, A. P., Bridgeman, A., Rosario, M., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.248 · Cited by 199 · see citing works

Self-replicating Semliki Forest virus RNA as recombinant vaccine

Zhou, X., Berglund, P., Rhodes, G., Parker, S. E., Jondal, M., & Liljeström, P. (1994) · Vaccine · doi:10.1016/0264-410x(94)90074-4 · Cited by 193 · see citing works

High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study

Bonjoch, A., Figueras, M., Estany, C., Pérez‐Álvarez, N., Rosales, J., del Río, L., Gregorio, S. D., Puig, J., Melis, G. G., Clotet, B., et al. (2010) · AIDS · doi:10.1097/qad.0b013e328340a28d · Cited by 166 · see citing works

T Cell Cross-Reactivity and Conformational Changes during TCR Engagement

Lee, J. K., Stewart-Jones, G., Dong, T., Harlos, K., di Gleria, K., Dorrell, L., Douek, D. C., van der Merwe, P. A., Jones, E. Y., & McMichael, A. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041251 · Cited by 161 · see citing works

Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads

Rolland, M., Heckerman, D. E., Deng, W., Rousseau, C. M., Coovadia, H. M., Bishop, K. S., Goulder, P., Walker, B. D., Brander, C., & Mullins, J. I. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001424 · Cited by 155 · see citing works

Definition of the viral targets of protective HIV-1-specific T cell responses

Mothe, B., Llano, A., Ibarrondo, J., Daniels, M., Miranda, C., Zamarreño, J., Bach, V., Zuñiga, R., Pérez-Álvarez, S., Berger, C. T., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-208 · Cited by 154 · see citing works

HIV-Host Interactions: Implications for Vaccine Design

Haynes, B. F., Shaw, G. M., Korber, B., Kelsoe, G. H., Sodroski, J., Hahn, B. H., Borrow, P., & McMichael, A. J. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.02.002 · Cited by 150 · see citing works

Staufen1 senses overall transcript secondary structure to regulate translation

Ricci, E. P., Küçükural, A., Cenik, C., Mercier, B. C., Singh, G., Heyer, E. E., Ashar-Patel, A., Peng, L., & Moore, M. J. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2739 · Cited by 130 · see citing works

Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection

Ondondo, B., Murakoshi, H., Clutton, G., Abdul-Jawad, S., Wee, E. G., Gatanaga, H., Oka, S., McMichael, A. J., Takiguchi, M., Korber, B., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.3 · Cited by 113 · see citing works

Lessons learned from HIV-1 vaccine trials: new priorities and directions

McMichael, A. J., & Haynes, B. F. (2012) · Nature Immunology · doi:10.1038/ni.2264 · Cited by 92 · see citing works

Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins

Beißert, T., Koste, L., Perković, M., Walzer, K. C., Erbar, S., Selmi, A., Diken, M., Kreiter, S., Türeci, Ö., & Şahin, U. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.121 · Cited by 81 · see citing works

Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial

Kibengo, F., Ruzagira, E., Katende, D., Naggirinya, A. B., Bahemuka, U. M., Haberer, J. E., Bangsberg, D. R., Barin, B., Rooney, J. F., Mark, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074314 · Cited by 80 · see citing works

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention

Baden, L. R., Karita, E., Mutua, G. N., Bekker, L., Gray, G., Page‐Shipp, L., Walsh, S. R., Nyombayire, J. M., Anzala, O. A., Roux, S., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-0880 · Cited by 80 · see citing works

Antiviral Inhibitory Capacity of CD8+ T cells Predicts the Rate of CD4+ T-Cell Decline in HIV-1 Infection

Yang, H., Wu, H., Hancock, G., Clutton, G., Sande, N., Xu, X., Yan, H., Huang, X., Angus, B., Kuldanek, K., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis379 · Cited by 79 · see citing works

Membrane Tumor Necrosis Factor (TNF) Induced Cooperative Signaling of TNFR60 and TNFR80 Favors Induction of Cell Death Rather Than Virus Production in HIV-infected T Cells

Lazdins, J. K., Grell, M., Walker, M. R., Woods-Cook, K., Scheurich, P., & Pfizenmaier, K. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.1.81 · Cited by 76 · see citing works

Long peptides induce polyfunctional T cells against conserved regions of HIV‐1 with superior breadth to single‐gene vaccines in macaques

Rosario, M., Bridgeman, A., Quakkelaar, E. D., Quigley, M. F., Hill, B. J., Knudsen, M. L., Ammendola, V., Ljungberg, K., Borthwick, N., Im, E., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.201040344 · Cited by 75 · see citing works

Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

Hayton, E., Rose, A., Ibrahimsa, U., Sorbo, M. D., Capone, S., Crook, A., Black, A. P., Dorrell, L., & Hanke, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101591 · Cited by 74 · see citing works

Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges

Im, E., Hong, J. P., Roshorm, Y. M., Bridgeman, A., Létourneau, S., Liljeström, P., Potash, M. J., Volsky, D. J., McMichael, A. J., & Hanke, T. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002041 · Cited by 65 · see citing works

Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential

Strenkowska, M., Grzela, R., Majewski, M., Wnek, K., Kowalska, J., Łukaszewicz, M., Zuberek, J., Darżynkiewicz, E., Kuhn, A. N., Şahin, U., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw896 · Cited by 63 · see citing works

Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines

Hanke, T. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.885946 · Cited by 61 · see citing works

Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes

Murakoshi, H., Akahoshi, T., Koyanagi, M., Chikata, T., Naruto, T., Maruyama, R., Tamura, Y., Ishizuka, N., Gatanaga, H., Oka, S., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00020-15 · Cited by 60 · see citing works

Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine

Knudsen, M. L., Mbewe‐Mvula, A., Rosario, M., Johansson, D. X., Kakoulidou, M., Bridgeman, A., Reyes‐Sandoval, A., Nicosia, A., Ljungberg, K., Hanke, T., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06535-11 · Cited by 50 · see citing works

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

Hancock, G., Yang, H., Yorke, E., Wainwright, E., Victoria, B., Frisbee, A. L., Payne, T. L., Berrong, M., Ferrari, G., Chopera, D., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004658 · Cited by 45 · see citing works

CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication

Murakoshi, H., Zou, C., Kuse, N., Akahoshi, T., Chikata, T., Gatanaga, H., Oka, S., Hanke, T., & Takiguchi, M. (2018) · Retrovirology · doi:10.1186/s12977-018-0429-y · Cited by 43 · see citing works

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults

Mutua, G. N., Farah, B., Langat, R., Indangasi, J., Ogola, S., Onsembe, B., Kopycinski, J. T., Hayes, P., Borthwick, N., Ashraf, A., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.61 · Cited by 40 · see citing works

The 'anti-hype' vaccine

DeFrancesco, L. (2017) · Nature Biotechnology · doi:10.1038/nbt.3812 · Cited by 38 · see citing works

Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition

Abdul-Jawad, S., Ondondo, B., van Hateren, A., Gardner, A., Elliott, T. J., Korber, B., & Hanke, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.210 · Cited by 36 · see citing works

Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines

Borthwick, N., Lin, Z., Akahoshi, T., Llano, A., Silva-Arrieta, S., Ahmed, T., Dorrell, L., Brander, C., Murakoshi, H., Takiguchi, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176418 · Cited by 35 · see citing works

Evaluation of the immunogenicity and impact on the latent HIV‐1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy‐treated subjects

Hancock, G., Morón‐López, S., Kopycinski, J. T., Puertas, M. C., Giannoulatou, E., Rose, A., Salgado, M., Hayton, E., Crook, A., Morgan, C., et al. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21171 · Cited by 33 · see citing works

The TNF receptor in TNF-mediated cytotoxicity.

Kull, F. C. (1988) · PubMed · Cited by 21 · see citing works

Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice

Ondondo, B., Abdul-Jawad, S., Bridgeman, A., & Hanke, T. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00587-14 · Cited by 20 · see citing works

HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells

Wee, E. G., Ondondo, B., Berglund, P., Archer, J. F., McMichael, A. J., Baltimore, D., ter Meulen, J. H., & Hanke, T. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.004 · Cited by 20 · see citing works

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice

Ondondo, B., Brennan, C., Nicosia, A., Crome, S. J., & Hanke, T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.06.068 · Cited by 12 · see citing works

Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines

Clutton, G., Carpov, A., Parks, C. L., Dean, H. J., Montefiori, D. C., & Hanke, T. (2014) · AIDS · doi:10.1097/qad.0000000000000468 · Cited by 10 · see citing works

Transient IL-10 receptor blockade can enhance CD8+T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen

Clutton, G., Bridgeman, A., Reyes‐Sandoval, A., Hanke, T., & Dorrell, L. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1009809 · Cited by 9 · see citing works

Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques

Borthwick, N., Rosario, M., Schiffner, T., Bowles, E. J., Ahmed, T., Liljeström, P., Stewart‐Jones, G. E., Drijfhout, J. W., Melief, C. J. M., & Hanke, T. (2015) · Immunity Inflammation and Disease · doi:10.1002/iid3.52 · Cited by 9 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

Advances in mRNA Vaccines for Infectious Diseases

Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 680 · see citing works

Advances in COVID-19 mRNA vaccine development

Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works

The Limitless Future of RNA Therapeutics

Damase, T. R., Sukhovershin, R. A., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 549 · see citing works

Self-amplifying RNA vaccines for infectious diseases

Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487 · see citing works

An Update on Self-Amplifying mRNA Vaccine Development

Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288 · see citing works

Formulation and Delivery Technologies for mRNA Vaccines

Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 221 · see citing works

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques

Zhang, P., Narayanan, E., Liu, Q., Tsybovsky, Y., Boswell, K. L., Ding, S., Hu, Z., Follmann, D. A., Lin, Y., Miao, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01574-5 · Cited by 164 · see citing works

Nanomedicine-Based Approaches for mRNA Delivery

Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139 · see citing works

An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery

Petkar, K. C., Patil, S. M., Chavhan, S. S., Kaneko, K., Sawant, K. K., Kunda, N. K., & Saleem, I. Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040455 · Cited by 103 · see citing works

Messenger RNA-Based Vaccines Against Infectious Diseases

Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96 · see citing works

Current approaches to HIV vaccine development: a narrative review

Kim, J., Vasan, S., Kim, J. H., & Ake, J. A. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25793 · Cited by 88 · see citing works

Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles

Melo, M., Porter, E., Zhang, Y., Silva, M., Li, N., Dobosh, B., Liguori, A., Skog, P., Landais, E., Menis, S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.007 · Cited by 88 · see citing works

A new generation of vaccines based on alphavirus self-amplifying RNA

Ballesteros-Briones, M. C., Silva-Pilipich, N., Herrador, G., Vanrell, L., & Smerdou, C. (2020) · Current Opinion in Virology · doi:10.1016/j.coviro.2020.08.003 · Cited by 87 · see citing works

Polysaccharide Nanoparticles Can Efficiently Modulate the Immune Response against an HIV Peptide Antigen

Dacoba, T. G., Omange, R. W., Li, H., Crecente‐Campo, J., Luo, M., & Alonso, M. J. (2019) · ACS Nano · doi:10.1021/acsnano.8b07662 · Cited by 82 · see citing works

Advanced technologies for the development of infectious disease vaccines

Gupta, A., Rudra, A., Reed, K., Langer, R., & Anderson, D. G. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01041-z · Cited by 85 · see citing works

HIV mRNA Vaccines—Progress and Future Paths

Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Vaccines · doi:10.3390/vaccines9020134 · Cited by 80 · see citing works

Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development

Schmidt, C., & Schnierle, B. S. (2023) · Pathogens · doi:10.3390/pathogens12010138 · Cited by 78 · see citing works

Self-Amplifying RNA Approach for Protein Replacement Therapy

Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76 · see citing works

The Delivery of mRNA Vaccines for Therapeutics

Nitika, Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12081254 · Cited by 70 · see citing works

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV

Matarazzo, L., & Bettencourt, P. J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172691 · Cited by 64 · see citing works

Prophylactic HIV-1 vaccine trials: past, present, and future

Nkolola, J. P., & Barouch, D. H. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00264-3 · Cited by 61 · see citing works

Self-amplifying mRNA vaccines: Mode of action, design, development and optimization

Pourseif, M. M., Masoudi‐Sobhanzadeh, Y., Azari, E., Parvizpour, S., Barar, J., Ansari, R. A., & Omidi, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103341 · Cited by 54 · see citing works

HIV vaccinology: 2021 update

Lee, J. H., & Crotty, S. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101470 · Cited by 52 · see citing works

Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application

Cordeiro, A. S., Patil‐Sen, Y., Shivkumar, M., Patel, R., Khedr, A., & Elsawy, M. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122091 · Cited by 50 · see citing works

Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action

Maruggi, G., Ulmer, J. B., Rappuoli, R., & Yu, D. L. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_233 · Cited by 45 · see citing works

Engineered mRNA Delivery Systems for Biomedical Applications

Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 44 · see citing works

In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future

Perenkov, A. D., Sergeeva, A. D., Vedunova, M. V., & Krysko, D. V. (2023) · Vaccines · doi:10.3390/vaccines11101600 · Cited by 40 · see citing works

The Repeated Setbacks of HIV Vaccine Development Laid the Groundwork for SARS-CoV-2 Vaccines

Harris, J. E. (2021) · National Bureau of Economic Research · doi:10.3386/w28587 · Cited by 37 · see citing works

Design-of-experiments in vitro transcription yield optimization of self-amplifying RNA

Samnuan, K., Blakney, A. K., McKay, P. F., & Shattock, R. J. (2022) · F1000Research · doi:10.12688/f1000research.75677.1 · Cited by 36 · see citing works

Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA

Aldon, Y., McKay, P. F., Herrero, J. M., Vogel, A. B., Lévai, R. F., Maisonnasse, P., Dereuddre‐Bosquet, N., Haas, H., Fábián, K., Grand, R. L., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.008 · Cited by 34 · see citing works

mRNA-based vaccine technology for HIV

Albert-Ludwigs-Universität Freiburg, G., Fortner, A., & Bucur, O. (2022) · Discoveries · doi:10.15190/d.2022.9 · Cited by 32 · see citing works

Innovations in HIV-1 Vaccine Design

Jones, L. D., Moody, M. A., & Thompson, A. B. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.01.009 · Cited by 32 · see citing works

Advances in mRNA and other vaccines against MERS-CoV

Tai, W., Zhang, X., Yang, Y., Zhu, J., & Du, L. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.007 · Cited by 32 · see citing works

Strategies for inducing effective neutralizing antibody responses against HIV-1

del Moral-Sánchez, I., & Sliepen, K. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1690458 · Cited by 31 · see citing works

Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses

Liu, Y., Li, Y., & Hu, Q. (2023) · Vaccines · doi:10.3390/vaccines11071142 · Cited by 27 · see citing works

mRNA-based HIV-1 vaccines

Ahmed, S., & Herschhorn, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-24 · Cited by 28 · see citing works

Advances in mRNA vaccines

Li, M., Wang, Z., Xie, C., & Xia, X. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.011 · Cited by 30 · see citing works

Advancing mRNA technologies for therapies and vaccines: An African context

Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25 · see citing works

Advancing mRNA vaccines: A comprehensive review of design, delivery, and efficacy in infectious diseases

Lu, Y., Qian, C., Huang, Y., Ren, T., Xie, W., Xia, N., & Li, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145501 · Cited by 26 · see citing works

In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?

Esteban, I., Pastor-Quiñones, C., Usero, L., Plana, M., García, F., & Leal, L. (2021) · Viruses · doi:10.3390/v13030501 · Cited by 26 · see citing works

Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection

Krähling, V., Erbar, S., Kupke, A., Nogueira, S. S., Walzer, K. C., Berger, H., Dietzel, E., Halwe, S., Rohde, C., Sauerhering, L., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.10.011 · Cited by 24 · see citing works

Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms

Wei, Q., Liu, S., Huang, X., Xin, H., & Ding, J. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.11.002 · Cited by 24 · see citing works

HIV and Messenger RNA Vaccine

Khalid, K., Padda, J., Khedr, A., Ismail, D., Zubair, U., Al-Ewaidat, O. A., Padda, S., Cooper, A. C., & Jean-Charles, G. (2021) · Cureus · doi:10.7759/cureus.16197 · Cited by 23 · see citing works

Trends in the synthetic polymer delivery of RNA

Friesen, J. J., & Blakney, A. K. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3672 · Cited by 20 · see citing works

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice

Kilpeläinen, A., Saubi, N., Guitart, N., Moyo, N. A., Wee, E. G., Ravi, K., Hanke, T., & Joseph, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00923 · Cited by 20 · see citing works

Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth

Moyo, N. A., Wee, E. G., Korber, B., Bahl, K., Falcone, S., Himansu, S., Wong, A. L., Dey, A., Feinberg, M. B., & Hanke, T. (2020) · Vaccines · doi:10.3390/vaccines8030360 · Cited by 20 · see citing works

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines

Elliott, T., Cheeseman, H. M., Evans, A. B., Day, S., McFarlane, L. R., O’Hara, J., Kalyan, M., Amini, F., Cole, T., Winston, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010885 · Cited by 21 · see citing works

Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV

D’haese, S., Lacroix, C., García, F., Plana, M., Ruță, S. M., Vanham, G. L., Verrier, B., & Aerts, J. L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.009 · Cited by 18 · see citing works

Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen

Casmil, I. C., Bathula, N. V., Huang, C., Wayne, C. J., Cairns, E. S., Friesen, J. J., Soriano, S. K. V., Liao, S., Ho, C., Kong, K. Y. S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.055 · Cited by 18 · see citing works

Emerging mRNA Technology for Liver Disease Therapy

Wang, J., Fang, Y., Luo, Z., Wang, J., & Zhao, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c02987 · Cited by 19 · see citing works

Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials

Akbari, E., Seyedinkhorasani, M., & Bolhassani, A. (2023) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2023.102774 · Cited by 17 · see citing works

HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies

Lau, J. S. Y., Lewin, S. R., & Telwatte, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1650852 · Cited by 19 · see citing works

The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines

Harris, J. E. (2022) · Health Policy and Technology · doi:10.1016/j.hlpt.2022.100619 · Cited by 15 · see citing works

The current and future role of nanovaccines in HIV-1 vaccine development

Karch, C. P., & Matyas, G. R. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1945448 · Cited by 14 · see citing works

Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review

Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16 · see citing works

Poly(2-oxazoline)/saRNA Polyplexes for Targeted and Nonviral Gene Delivery

Hayes, G., Barbieri, B. D., Yilmaz, G., Shattock, R. J., & Becer, C. R. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.3c00683 · Cited by 14 · see citing works

Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines

Wee, E. G., Moyo, N. A., Hannoun, Z., Giorgi, E. E., Korber, B., & Hanke, T. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.018 · Cited by 14 · see citing works

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines

del Moral-Sánchez, I., Wee, E. G., Xian, Y., Lee, W.-H., Allen, J. D., Torrents de la Peña, A., Fróes Rocha, R., Ferguson, J., León, A. N., Koekkoek, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00862-8 · Cited by 14 · see citing works

Virus-Like Vesicles Based on Semliki Forest Virus-Containing Rabies Virus Glycoprotein Make a Safe and Efficacious Rabies Vaccine Candidate in a Mouse Model

Zhang, C., Tian, Y., Chen, C., Wang, Z., Pei, J., Lin, C., Zhou, M., Fu, Z. F., & Zhao, L. (2021) · Journal of Virology · doi:10.1128/jvi.00790-21 · Cited by 13 · see citing works

Advanced nanoscale delivery systems for mRNA-based vaccines

Mobasher, M., Ansari, R. A., Castejon, A. M., Barar, J., & Omidi, Y. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130558 · Cited by 13 · see citing works

mRNA vaccine platforms and novel delivery systems: From mechanistic principles to clinical translation

Yang, Y., Sun, Y., Kang, X., & Wang, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2597629 · Cited by 17 · see citing works

Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes

García-Bates, T. M., Palma, M. L., Anderko, R. R., Hsu, D. C., Ananworanich, J., Korber, B., Gaiha, G. D., Phanuphak, N., Thomas, R., Tovanabutra, S., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2020.103175 · Cited by 12 · see citing works

Efficient Induction of Antigen-Specific CD8+ T-Cell Responses by Cationic Peptide-Based mRNA Nanoparticles

D’haese, S., Laeremans, T., den Roover, S., Allard, S. D., Vanham, G. L., & Aerts, J. L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071387 · Cited by 10 · see citing works

Targeting HIV-1 immune escape mechanisms: Key advances and challenges in HIV-1 vaccine design

Fang, Z., Jiang, W., Liu, P., Xia, N., Li, S., & Gu, Y. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128229 · Cited by 10 · see citing works

Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses

Borgo, G. M., & Rutishauser, R. L. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000824 · Cited by 9 · see citing works

Induction of a Robust Humoral Response using HIV-1 VLPMPER-V3as a Novel Candidate Vaccine in BALB/c Mice

Tohidi, F., Sadat, S. M., Bolhassani, A., Yaghobi, R., & Larijani, M. S. (2019) · Current HIV Research · doi:10.2174/1570162x17666190306124218 · Cited by 9 · see citing works

Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques

Murakowski, D. K., Barton, J. P., Peter, L. E., Chandrashekar, A., Bondzie, E. A., Gao, A., Barouch, D. H., & Chakraborty, A. K. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022496118 · Cited by 9 · see citing works

mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic

Chen, P., Shi, X., He, W., Zhong, G., Tang, Y., Wang, H., & Zhang, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2040330 · Cited by 10 · see citing works

Harnessing the Potential of mRNA Vaccines Against Infectious Diseases

Rezk, N., & McClean, S. (2025) · Microbial Biotechnology · doi:10.1111/1751-7915.70212 · Cited by 8 · see citing works

Mechanism for evolution of diverse autologous antibodies upon broadly neutralizing antibody therapy of people with HIV

Kannan, D., Wang, E. J. D., Deeks, S. G., Lewin, S. R., & Chakraborty, A. K. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116545 · Cited by 8 · see citing works

Nano-vaccines for gene delivery against HIV-1 infection

Li, S., Zhang, M., Yuan, J., & Zhang, Y.-X. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2193266 · Cited by 8 · see citing works

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1

Wee, E. G., Moyo, N. A., Saunders, K. O., LaBranche, C. C., Donati, F., Capucci, S., Parks, R., Borthwick, N., Hannoun, Z., Montefiori, D. C., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.003 · Cited by 7 · see citing works

Development of universal influenza vaccines: strategies for broadly cross-reactive influenza vaccine responses

Li, M., Guo, P., Song, H., Chen, C., Zhou, H., & Pan, T. (2025) · Animal Diseases · doi:10.1186/s44149-025-00187-6 · Cited by 6 · see citing works

The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs

D’haese, S., den Roover, S., Verbeke, R., Aernout, I., Meulewaeter, S., Cosyns, J., Meert, J., Vanbellingen, S., Laeremans, T., Lentacker, I., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102372 · Cited by 6 · see citing works

Advances in the treatment and prevention of HIV: what you need to know

Colloty, J., Teixeira, M., & Hunt, R. (2023) · British Journal of Hospital Medicine · doi:10.12968/hmed.2022.0502 · Cited by 5 · see citing works

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa

Beavis, A. C., Wee, E. G., Yildirim, B. M. A., Borthwick, N., He, B., & Hanke, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1186478 · Cited by 4 · see citing works

Silica Nanoparticles as Multifunctional Platforms for Vaccine Delivery and Immune Modulation in Infectious Diseases

Mendoza‐Ramírez, N. J., García‐Cordero, J., Navarro‐Tovar, G., & Cedillo‐Barrón, L. (2025) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500126 · Cited by 3 · see citing works

A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine

Pather, S., Charpentier, N., van den Ouweland, F., Rizzi, R., Finlayson, A., Salisch, N. C., Muik, A., Lindemann, C., Khanim, R., Abdul-Jawad, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126165 · Cited by 3 · see citing works

Strategies for HIV-1 suppression through key genes and cell therapy

Sorokina, A. V., Anchakova, E., & Dashinimaev, E. B. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1259995 · Cited by 4 · see citing works

Application of self-amplifying mRNA technology in the development of infectious disease vaccines

Li, X., Wang, X., & Zhang, B. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0902 · Cited by 2 · see citing works

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses

Olvera, À., Romero-Martín, L., Oriol-Tordera, B., Rosás-Umbert, M., Escribà, T., Mothe, B., & Brander, C. (2024) · Vaccines · doi:10.3390/vaccines12030279 · Cited by 2 · see citing works

Advancing Protein‐Coding RNA Engineering: From Structural Refinement to Biomedical Implementation

Lu, X., Li, S., Chi, Y., Lin, S., Yuan, H., Lin, Z., Xiao, Y., Yin, H., Zuo, X., Cheng, R., et al. (2025) · Biotechnology Journal · doi:10.1002/biot.70038 · Cited by 2 · see citing works

Modular design of a self-amplifying mRNA vaccine for multivalent immunization against Neisseria meningitidis B

Chen, G., Chen, G., Wang, S., Xing, R., Yang, Y., Zhou, R., Ma, L., Wang, X., Wang, Y., Song, W., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127964 · Cited by 1 · see citing works

RNA therapeutics for infectious diseases

Tu, L. M. T. P. P. L. M., Pham, T. T. D., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.002 · Cited by 1 · see citing works

pDNA and mRNA vaccines

Gill, K., Minall, L., & Nassif, A. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814357-5.00007-6 · Cited by 1 · see citing works

mRNA疗法的研究进展与挑战

Fu, J., Feng, S., Du, B., Dong, H., Lin, J., & Yongfeng, J. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0376 · Cited by 1 · see citing works

mRNA Vaccines for HIV‐1

Lusso, P. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch9 · Cited by 1 · see citing works

Worldwide Overview of the Different COVID-19 Vaccine Platforms:A Review and Reflection on the Current Evidence

Liebisch-Rey, H., Bustos, J. F., Salazar-Reggeti, R., Pérez, J. A. V., Isaza, E. R., Vargas, M. A. C., Silva-Amaro, A. C., González, V. I. M., Moreno, L. B., Abreu, D. A. R. D., et al. (2021) · Salud Uninorte · doi:10.14482/sun.37.1.616.241

mRNA-based nanovaccines as newer treatment modalities in cancer

Dubey, A. K., Das, S. S., Hosseinpour, M., Verma, P. R. P., Singh, S. K., & Singh, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823686-4.00006-9

Tracing the recent updates on vaccination approaches and significant adjuvants being developed against HIV

Malik, S., Muhammad, K., Aslam, S. M., & Waheed, Y. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2182771

HIV Pol: does it offer therapeutic targets for HIV?

Muccini, C., & Castagna, A. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2351510

Self-amplifying mRNA expression is governed by mitochondrial machinery and ACSL4Preprint

Tshering, L. F., Wang, C., Xiang, Q., Kundu, S., Solórzano, A., Chaparro‐Riggers, J. F., Lin, L., & Paksa, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.659366

Myths and Facts Associated with Vaccine Development: Challenges, Safety, and Efficacy

Vihal, S., Kaur, S. D., Vivek, P., Kumari, N., Kumbham, S., & Salihu, M. B. (2026) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-032-29006-9_15

Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth

Moyo, N. A., Wee, E. G., Korber, B., Bahl, K., Falcone, S., Himansu, S., Wong, A. L., Dey, A., Feinberg, M. B., & Hanke, T. (2020) · Vaccines · doi:10.3390/vaccines8030360 · Cited by 20 · see citing works

Self-amplifying RNA-based activation of HIV-1 broadly neutralizing antibody B cell precursors 2690

Agrawal, P., Means, M. M., Fields, R., Hinton, K., Khechaduri, A., Salladay, K. R., Rose, J. A., Voigt, E. A., Melief, E. H., Press, C., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf283.579

Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA

Aldon, Y., McKay, P. F., Herrero, J. M., Vogel, A. B., Lévai, R. F., Maisonnasse, P., Dereuddre‐Bosquet, N., Haas, H., Fábián, K., Grand, R. L., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.008 · Cited by 34 · see citing works

Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice

Ondondo, B., Abdul-Jawad, S., Bridgeman, A., & Hanke, T. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00587-14 · Cited by 20 · see citing works

Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection

Ondondo, B., Murakoshi, H., Clutton, G., Abdul-Jawad, S., Wee, E. G., Gatanaga, H., Oka, S., McMichael, A. J., Takiguchi, M., Korber, B., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.3 · Cited by 113 · see citing works